Case ID:
2009-1204
Web Published:
10/13/2011
Diagnostic for Progression of
Fatty Liver Disease
(CHMC Ref. Id: 2009-1204)
Overview:
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease worldwide today. However, there is currently no widely validated
and reliable non-invasive biomarker for fibrosis progression in non-alcoholic
steatohepatitis (NASH), the more advanced and progressive phenotype of
NAFLD. The current method of determining severity involves the use of
liver biopsies, which are invasive and risky procedures. This technology
identifies a protein present in the plasma/serum of an animal model of NAFLD
that can predict the progression of the disease. The data show that the
NAFLD animals had advanced fibrosis and significantly higher levels of the
identified protein than their study counterparts.
Applications:
- Diagnostic for NAFLD
- Indicator of fibrosis progression in NAFLD and potentially other chronic
liver diseases
Advantages:
- Non-invasive
- Eliminates the need for liver biopsy
- May be useful for staging the progression and extent of fibrosis for
chronic liver diseases secondary to any etiology
Patent Information:
- Patent Applications Pending
Cincinnati Children's Lead
Inventor:
Rohit Kohli, MBBS, MS
Patent Information:
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
